Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism

J Gynecol Oncol. 2018 Mar;29(2):e32. doi: 10.3802/jgo.2018.29.e32.

Abstract

Ovarian cancer is most deadly gynecologic malignancies worldwide. Chemotherapy is the mainstay treatment for ovarian cancer. Despite the initial response is promising, frequent recurrence in patients with advanced diseases remains a therapeutic challenge. Thus, understanding the biology of chemoresistance is of great importance to overcome this challenge and will conceivably benefit the survival of ovarian cancer patients. Although mechanisms underlying the development of chemoresistance are still ambiguous, accumulating evidence has supported an integral role of cancer stem cells (CSCs) in recurrence following chemotherapy. Recently, tumor metabolism has gained interest as a reason of chemoresistance in tumors and chemotherapeutic drugs in combination with metabolism targeting approaches has been found promising in overcoming therapeutic resistance. In this review, we will summarize recent studies on CSCs and metabolism in ovarian cancer and discuss possible role of CSCs metabolism in chemoresistance.

Keywords: Cancer Stem Cells; Drug Resistance, Neoplasm; Metabolism; Ovarian Neoplasms.

Publication types

  • Review

MeSH terms

  • 3-Phosphoinositide-Dependent Protein Kinases / antagonists & inhibitors
  • Antineoplastic Agents
  • Drug Resistance, Neoplasm*
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Glycolysis / drug effects
  • Humans
  • Neoplasm Recurrence, Local
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / metabolism*
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / metabolism
  • Oxidative Phosphorylation / drug effects

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • 3-Phosphoinositide-Dependent Protein Kinases
  • PDPK1 protein, human